PHILADELPHIA CREAM, June 16, 2021 / PRNewswire / – Enterin, Inc., a clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative diseases, announces that the company will make a presentation at the JMP Securities Life Sciences conference on Thursday June 17th at 3:00 p.m. EDT.
Dr. Denise barbut, co-founder, President and CMO of Enterin, will present the company.
About Enterin, Inc.
Enterin, Inc. is developing new compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin, Inc. is a pioneer in the medical community’s understanding of the link between infections, enteric nervous system (ENS) dysfunction and the early symptoms and progression of neurodegenerative diseases. The main compound, ENT-01, displaces membrane-bound alpha-synuclein (aS) aggregates from ENS nerve cells and improves neuronal signaling between the gut and brain in preclinical models of Parkinson’s disease and in human studies. Enterin, Inc. is now advancing ENT-01 through clinical trials with the goal of reversing the neurological symptoms of Parkinson’s disease. A second compound, ENT-03, reverses central insulin resistance, the central pathology in conditions ranging from obesity to diabetes to Alzheimer’s disease. In animal models of Alzheimer’s disease, ENT-03 normalizes memory and prolongs life. The first studies in humans will begin at 1H 2022.
For more information, please visit www.enterininc.com.
View original content to download multimedia: http://www.prnewswire.com/news-releases/enterin-to-present-at-jmp-securities-life-sciences-conference-301313496.html
SOURCE Enterin, Inc.